A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.
Michael Ong
No relevant relationships to disclose
Gianluca Del Conte
No relevant relationships to disclose
Rastislav Bahleda
No relevant relationships to disclose
Joaquin Mateo
No relevant relationships to disclose
Silvia Damian
No relevant relationships to disclose
Antonella Perotti
No relevant relationships to disclose
Nathalie Lassau
No relevant relationships to disclose
Françoise Farace
No relevant relationships to disclose
Jimena Lovosgaldeano
No relevant relationships to disclose
Nina Tunariu
No relevant relationships to disclose
Marie Hospitel
Employment or Leadership Position - Sanofi
Paola Mariani
No relevant relationships to disclose
Patrick Cohen
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Giuseppe Capri
No relevant relationships to disclose
Jean-Charles Soria
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Luca Gianni
No relevant relationships to disclose
L Rhoda Molife
No relevant relationships to disclose
Cristiana Sessa
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi